Gangatharan Mathisuthan, MD
Internal Medicine · Mullins, SCNPI 1982668745
Payments from drug & device makers
Across 83 payments — averaging $77.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Novartis$801
- Novo Nordisk$336
- Sunovion Pharmaceuticals Inc.$263
- GSK$102
- Astellas Pharma US Inc$79
- plus $354 from 14 others
What the payments were for
- Consulting fees$4,07463%
- Travel & lodging$89214%
- Food & beverage$1,46523%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $4,521 |
| Novartis | 2 | $801 |
| Novo Nordisk | 9 | $336 |
| Sunovion Pharmaceuticals Inc. | 19 | $263 |
| GSK | 5 | $102 |
| Astellas Pharma US Inc | 4 | $79 |
| Johnson & Johnson | 4 | $69 |
| Pfizer | 3 | $38 |
| Lilly USA, LLC | 3 | $34 |
| Amarin Pharma, Inc. | 2 | $31 |
| Merck | 2 | $31 |
| Amgen | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $26 |
| Boehringer Ingelheim | 1 | $17 |
| Mannkind Corporation | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| AbbVie | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,455 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 550 | $632,123 |
| EntrestoSacubitril/Valsartan | 320 | $272,926 |
| EliquisApixaban | 267 | $236,340 |
| PromactaEltrombopag Olamine | 12 | $216,278 |
| JardianceEmpagliflozin | 235 | $200,335 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 194 | $155,385 |
| LinzessLinaclotide | 234 | $153,074 |
| SynjardyEmpagliflozin/Metformin Hcl | 137 | $105,327 |
| TrulicityDulaglutide | 82 | $101,301 |
| MounjaroTirzepatide | 68 | $94,996 |
| Repatha SureclickEvolocumab | 63 | $81,067 |
| XareltoRivaroxaban | 113 | $77,811 |
| JanumetSitagliptin Phos/Metformin Hcl | 103 | $66,015 |
| MyrbetriqMirabegron | 91 | $62,539 |
| RinvoqUpadacitinib | 12 | $54,698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $336 | $632,123550 claims |
| NovartisEntresto, Promacta | $801 | $489,204332 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Combivent Respimat, Stiolto Respimat | $17 | $359,651437 claims |
| AbbVieLinzess, Rinvoq, Viberzi, Vraylar, Namzaric | $11 | $259,604286 claims |
| PfizerEliquis | $38 | $236,340267 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $34 | $196,297150 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $102 | $164,956210 claims |
| MerckJanumet, Januvia, Janumet Xr | $31 | $133,160180 claims |
| Johnson & JohnsonXarelto | $69 | $77,811113 claims |
| Astellas Pharma US IncMyrbetriq | $79 | $62,53991 claims |
| AstraZenecaFarxiga, Symbicort | $4,521 | $50,57985 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $16 | $10,42912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Mullins
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
- Jerry BackNorth Charleston$322K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.